
Dr. Antoni Villaverde: Protein-Based Therapeutic Killing for Cancer Therapies
Protein-Based Therapeutic Killing for Cancer Therapies
Naroa Serna1, Laura Sánchez-García, Ugutz Unzueta, Raquel Díaz, Esther Vázquez, Ramón Mangues, Antonio Villaverde
Show more
https://doi.org/10.1016/j.tibtech.2017.11.007
Targeting cytotoxic drugs in oncology is essential because side toxicities limit reaching effective local doses.
Functionalization of nanoscale drug vehicles has so far achieved a moderate targeting effect. The nanoscale size of drug preparations favors enhanced permeability and retention (EPR) and reduces renal filtration.
Proteins are used as inert nanoscale carriers and as functional targeting agents in the form of antibodies or ligands that bind to tumor cell-surface markers.
Many protein species exhibit potent cytotoxic ac